Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on ...

"How cells prevent separation of broken DNA ends has been somewhat of a mystery. My team has found that it is thanks to a ...

On one hand, it represses PARP1 catalytic activity and associated DNA damage repair. On the other hand, it also protects cells from overconsuming nicotinamide adenine dinucleotide—a coenzyme ...

Investigators at the Third People’s Hospital of Chengdu and collaborators described the synergistic effect obtained by the combined administration of LB-23, a PARP1 degrader, and JQ1, a BRD4 inhibitor ...

The PARP protein family comprises 17 members, but PARP1 and PARP2 are the main proteins involved in DNA repair. Both proteins regulate the DDR network, but PARP1 also regulates transcription and ...

本研究合成的PROTAC 180055可有效且选择性地降解PARP1、抑制其活性，无DNA捕获效应，在体内外对BRCA突变肿瘤细胞具杀伤性且对正常细胞影响小 ...

AZ has been presenting preclinical data from AZD5305, its next-generation PARP1 inhibitor at the 2021 American Association for Cancer Research meeting, which the company thinks could be more ...

So, as BRCA-deficient cells had previously been shown to be highly sensitive to the effects of inhibiting PARP1, Rottenberg and colleagues investigated the effects of the PARP1 inhibitor AZD2281 ...

Merck gets exclusive rights to Hengrui’s PARP1 drug HRS-1167 outside China under the terms of the agreement, and also picks up an option for an ex-China license to SHR-A1904, an ADC directed at ...